📈 HiSCR Calculator

Hidradenitis Suppurativa Clinical Response — Kimball et al., 2016

Purpose
Assesses treatment response in HS by comparing lesion counts at baseline and follow-up.
Population
HS patients receiving active treatment. Requires minimum AN count ≥ 3 at baseline for assessability in trials.
Response criterion
HiSCR = ≥ 50% ↓ AN count AND no increase in abscesses AND no increase in draining tunnels vs. baseline
Definition of AN
AN = Abscesses + Inflammatory Nodules (does not include non-inflammatory nodules)
📍 Baseline (Pre-treatment)
Inflammatory nodules (IN)
0
Abscesses (AB)
0
Draining tunnels (DT)
0
AN count (IN + AB) 0
📊 Current / Follow-up
Inflammatory nodules (IN)
0
Abscesses (AB)
0
Draining tunnels (DT)
0
AN count (IN + AB) 0
📚 References
  1. Kimball AB, Jemec GBE, Yang M, et al. Efficacy and safety of adalimumab for the treatment of hidradenitis suppurativa: a phase 2 dose-ranging study. Br J Dermatol. 2011;165(2):391–9.
  2. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–34.
  3. Zouboulis CC, et al. S2k guidelines for the treatment of hidradenitis suppurativa/acne inversa. J Dtsch Dermatol Ges. 2024.
  4. Zouboulis CC, Gulliver W, Ingram J, et al. Endpoints of clinical trials for hidradenitis suppurativa. Exp Dermatol. 2020;29(Suppl 1):67–72.
Clinical decision support only. This tool is intended to assist clinical assessment and does not replace professional judgment. Always interpret results in the context of the individual patient.